@article{23610c58026a451eabcd677fe14588b3,
title = "Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features",
abstract = "Objectives: As the world transitions into a new era of the COVID-19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. Methods: We used 34 SARS-CoV-2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level-3 containment. We correlated results from the sVNT with five additional commonly used SARS-CoV-2 serology techniques: the microneutralisation test (MNT), in-house ELISAs, commercial Euroimmun- and Wantai-based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen-binding avidity, and high-throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody-secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. Results: Antibody data obtained with commercial ELISAs closely reflected results using in-house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike-specific IgG and IgA titres detected by both commercial and in-house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh-type 1 cell numbers correlated with spike and RBD-specific IgG antibodies measured by ELISAs and sVNT. Conclusion: Our comprehensive analyses provide important insights into SARS-CoV-2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS-CoV-2-specific humoral responses.",
keywords = "ELISA, SARS-CoV-2 antibodies, T follicular helper cells, antibody-secreting cells, neutralisation assay",
author = "Rowntree, {Louise C.} and Chua, {Brendon Y.} and Suellen Nicholson and Marios Koutsakos and Luca Hensen and Celia Douros and Kevin Selva and Mordant, {Francesca L.} and Wong, {Chinn Yi} and Habel, {Jennifer R.} and Wuji Zhang and Xiaoxiao Jia and Lily Allen and Doolan, {Denise L.} and Jackson, {David C.} and Wheatley, {Adam K.} and Kent, {Stephen J.} and Fatima Amanat and Florian Krammer and Kanta Subbarao and Cheng, {Allen C.} and Chung, {Amy W.} and Mike Catton and Nguyen, {Thi H.O.} and {van de Sandt}, {Carolien E.} and Katherine Kedzierska",
note = "Funding Information: We thank all the participants involved in the study; Bernie McCudden and Jenny Mitchell for support with the cohort; and Jill Garlick, Janine Roney, Anne Paterson and the research nurses at the Alfred Hospital. This work was supported by the Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grant to KK (#1173871), NHMRC Program Grant to DLD (#1132975), Research Grants Council of the Hong Kong Special Administrative Region, China (#T11‐712/19‐Ncdf) to KK, the Jack Ma Foundation to KK, KS and AWC, the Medical Research Future Fund (#2005544) to KK, SJK, AKW and AWC, the a2 Milk Foundation to KS, MRFF Award (#1202445) to KK, NHMRC Program Grant (#1071916) to KK. KK was supported by NHMRC Senior Research Fellowship (1102792), DLD by a NHMRC Principal Research Fellowship (#1137285) and KS by an NHMRC Investigator grant (#1177174). THON is supported by NHMRC EL1 Fellowship (#1194036). LH is supported by the Melbourne International Research Scholarship (MIRS) and the Melbourne International Fee Remission Scholarship from The University of Melbourne. JRH and WZ are supported by the Melbourne Research Scholarship from The University of Melbourne. XJ is supported by China Scholarship Council‐University of Melbourne joint Scholarship. CES has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska‐Curie grant agreement (#792532). CES and KS received funding from the Doherty Collaborative Seed Grant. KK and AWC were supported by the University of Melbourne Dame Kate Campbell Fellowship. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. Publisher Copyright: {\textcopyright} 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.",
year = "2021",
doi = "10.1002/cti2.1258",
language = "English",
volume = "10",
journal = "Clinical and Translational Immunology",
issn = "2050-0068",
publisher = "John Wiley & Sons Inc.",
number = "3",
}